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Cancer invasion involves a series of fundamental heterogeneous steps, with each step being distinct in its
type regarding its dependence on various oncogenic pathways. Over the past few years, researchers have
been focusing on targeted therapies to treat malignancies relying not only on a single oncogenic
pathway, but on multiple pathways. Scientists have recently identiﬁed potential targets in the human
genome considered earlier as non-functional but the discovery of their potential role in gene regulation
has put new insights to cancer diagnosis, prognosis and therapeutics. Non coding RNAs (ncRNAs) have
been identiﬁed as the key gene expression regulators. Long non-coding RNA (lncRNAs) reveal diverse
gene expression proﬁles in benign and metastatic tumours. Improved clinical research may lead to better
knowledge of their biogenesis and mechanism and eventually be used as diagnostic biomarkers and
therapeutic agents. Small non coding RNAs or micro RNA (miRNA) are capable of reprogramming mul-
tiple oncogenic cascades and, thus, can be used as target agents. This review is aimed to give a
perspective of non coding transcription in cancer metastasis with an eye on rising clinical relevance of
non coding RNAs and their mechanism of action focusing on potential therapeutics for cancer
pathogenesis.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).1. Introduction
Uncontrolled cellular proliferation and inhibition of apoptosis in
cells results in the development of tumorigenesis which ultimately
leads to the formation of cancer. The hallmark of cancer is the
metastasis [1]. Major hindrance to the treatment of metastasis is
that cancer cells show biological heterogeneity due to which it is
most probably diagnosed at the later stages. Several regulatory
factors called oncogenes regulate the proliferation and apoptotic
mechanisms by working as tumour promoter genes. The emerging
focus of the scientists is to identify certain biomarkers of the cancer
related protein coding genes [2]. Only 2% of the entire human
genome represents protein coding genes containing 20,000 genes.
nications Co., Ltd.
ing by Elsevier B.V. on behalf of Ke
d/4.0/).
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These non coding RNAs (ncRNAs) are not meant to transcribe into
proteins but they have a signiﬁcant role in the transcription of
protein coding transcripts into RNA and translation into functional
proteins [3]. The classiﬁcation of ncRNAs is based upon the targets
and functions of the ncRNA molecules i.e. small non coding RNAs
called micro RNAs (miRNAs) and long non coding RNAs (lncRNAs).
The last version 23 of the Ensemble human genome annotation
from March 2015 i.e. GRch38 identiﬁes that there are 27,817
lncRNAs transcripts emerging from 15,931 genes. The number
lncRNAs in the human genome is signiﬁcantly greater than the
protein coding genes which exhibit a structure similar to mRNA
consisting of poly A tail [4]. Further lncRNAs is classiﬁed into ﬁve
categories i.e Intergenic lnc RNAs (present between two protein
coding genes), Intronic lncRNAs (introns of protein coding genes
transcribe them), Overlapping lncRNAs (a coding gene is located on
the intron), Antisense lncRNAs (the opposite strand of proteinAi Communications Co., Ltd. This is an open access article under the CC BY-NC-ND
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open reading frame ORF) [5]. The functions of lncRNAs are quite
intricate. Those lncRNAs which lack an ORF regulate epigenetics,
transcription, and post transcriptional modiﬁcation of RNA genetic
expressions in response to vast regulating cues. Therefore, they are
sometimes misexpressed in leukemias and primary solid tumours.
The expression of many HOX lncRNAs is investigated to be different
in solid breast tumours and isolated metastasis regions. The DNA
damage in response to carcinogenesis involves p-53 dependent
lncRNAs. Many transcriptional variations are under the control of
lncRNAs which implies that there is a difference of lncRNAs
proﬁling between normal and carcinogenic cells and lncRNAs are
strictly linked with cancer metastasis and progression [6]. There-
fore, the differential proﬁling of lncRNAs expression in normal and
cancer cells provides a good biomarker of cancer diagnosis and
developing a reasonable therapeutic approach.
Recent studies indicate that other small non coding protein
RNAs called micro RNAs (mi RNAs) also aid in tumour suppression
and are recognised as one of the largest gene regulators. They
comprise approximately 1e4% of the total human genome and are
almost 300 in number. The location of existence of miRNAs is on the
introns of the non-coding mRNA genes and on the exons of the
non-coding mRNA transcripts or either are present at 3' UTR of
mRNA transcripts. miRNAs are involved to target multiple genes.
However, the identiﬁcation of these multiple target genes is
somewhat difﬁcult because they show partial complementarity
with miRNA due to which mismatched and G-U base pairing hap-
pens. A simple bioinformatics tool, such as BLAST, is unable to
identify the miRNA gene targets [7]. Due to this fact, it is
acknowledged that miRNA 5' end depicts the greatest homologous
relationship in the whole family. Recent research have also dis-
closed the important fact of 5' end of mRNA which aids in the
loading and stability of miRNA into the miRISC complex system
which is of biological importance. This is the reason why most
bioinformatics tools use the initial 2e8 bases of miRNA sequence to
ﬁnd sequence complementarity in the 3'end of UTR for all the
target genes. All this research has revealed that a single strand of
miRNA can target approximately 200 gene sequences, irrespective
of the diversity in target genes' functions i.e. they might be re-
ceptors, transcription factors or secreted molecules. Therefore, it
can be inferred that mi RNA has enormous potential to regulate the
expression of about one-third of human mRNA [8].
The biological role of miRNAs is to regulate the processes
associated with cancer growth, such as tissue growth and differ-
entiation. Such miRs playing crucial role in cancer development are
also termed as oncomirs. These oncomirs encoded by lin-4and let-7
control the cellular proliferation and differentiation in C.elegans.
Certain mutations, when appearing in these miRNA genes, result in
the development of some abnormalities in the cell cycle arrest
which is the hallmark of cancer. Interestingly, a similar fact became
known when the function of the lin-4 and let-7 encoded oncomirs
was studied that they are strictly related to distinct types of cancers.
Several studies have revealed that miRNAs are identiﬁed in the
serum, peripheral blood circulation, mononuclear cells and whole
blood of cancer patients, such as breast cancer (miRNA-195 and let-
7a), lung carcinoma (miR-21, miR-210 and miR-486-5p) and pros-
tate cancer (miR-141) [9]. Hence, these miRNA signatures are
regarded as diagnostic biomarkers of miRNA detection to differ-
entiate cancer patients from normal individuals. A new evolving
concept of circulating miRNA detection in exosomes links miRNA to
cell to cell communication. Exosomes are relatively small vesicles
containing apoptotic bodies and endosomes including macro-
phages, platelets and tumour cells. Recently, it was studied that
exosomes also consist of miRNA, mRNA, proteins and lipids which
renders them to be multivariate molecules [10].Please cite this article in press as: M. Rasool, et al., Non-coding RNAs in ca
dx.doi.org/10.1016/j.ncrna.2016.11.001Therapeutics of cancer based miRNA is studied on two levels i.e.
either over expression of miRNA tumour suppressor or silencing
oncogenic miRNA, both in vivo or in vitro approaches. Recent in-
vestigations disclosed the role of transgenic and knock out
modelling in the mechanism of a speciﬁc miRNA. For instance, in a
murine model driven by Kras, the over expression of miR-21
(oncomirs) up regulates the tumerogenesis, whereas its targeted
deletion decreased the formation of tumours in the lungs. The most
successful application of miRNA targeted therapeutics updated is
the treatment of chronic hepatocellular carcinoma by delivering
liver speciﬁc DNA-LNA (Locked Nucleic acids) miR-122 anti miRNA
(SPC3649) as theranostic tool in chronic HCV infected model, but
some issues of target toxicity and organ speciﬁcity may also persist.
The other method of miRNA targeting is through delivery of
cholesterol bound 2-O-methyl antagomiRs, which maintain the
delivery and stability by decreasing degradation. On the other
hand, miRNA targeting through Lock Nucleic Acids (LNAs) is more
potent functionally, which locks ribose active sites by methylene
bridges. The simplest way of miRNA targeted delivery is through
Anti-miRNA oligonucleotides (AMOs) by direct complementarity,
thus, inhibiting the target miRNA [11].
2. Molecular mechanism and genetic modiﬁcation by
lncRNAs in cancer
2.1. Deregulation of oncogene HOX-transcript antisense RNA
(HOTAIR)
The molecular mechanism of long non coding RNA is strictly
based upon controlling the gene expression by direct recruitment
of histone modiﬁcation enzymes to cell chromatin. DNA methyl-
ation and the resulting chromatin modiﬁcation signatures the post
translational modiﬁcation which renders the protein product to be
functional. The functional turmoil of these epigenetic changes is the
key to the development of carcinogenesis. However, the rate at
which DNA mutations occur in somatic cells is much lesser than
these epigenetic changes in the cell. That is why these alterations
are much more stable and can be inherited through generations.
Functional alterations in lncRNAs provide the suitable environment
for cells to proliferate undifferentially, leading the path towards
tumerogenesis. Here we are explaining this mechanism with the
help of an example: An oncogenic long non coding RNA called HOX
transcript antisense RNA (HOTAIR) reprograms the state of chro-
matin promoting cancer metastasis highly expressed in predis-
posed breast cancer metastasis [12]. Molecular mechanism of this
metastasis by HOTAIR is that when it is highly expressed a poly-
comb repressive complex 2 (PRC2) consisting of methylase EZH2,
SUZ12 and EED bring about genetic expression changes via H3K27
methylation which grades the upregulation of cancer metastasis in
vivo. Therefore, disappearance or disturbance in the gene expres-
sion of HOTAIR or associated PRC2 complex components inhibits
cancer metastasis.It is concluded that lncRNAs are potentially
involved in the progression of cancer invasiveness and its thera-
peutics can be designed by deregulation or disturbance of gene
expression of HOTAIR to stop cancer invasiveness. HOTAIR is known
to be the ﬁrst identiﬁed lncRNAs functional in trans form. However,
other antisense lncRNAs are identiﬁed to be the gene silencer in cis
form. For instance, the transcription of tumor suppressor genes
CDKN2B and CDKN2A produce antisense ANRIL which brings
interaction with a subunit of PRC1 (CBX7). This results in gene
silencing and the production of heterochromatin in cancer cells.
Thus antisense HOTAIR works as an oncogene silencer by carrying
about epigenetic changes in chromatin and DNA methylation.
LNCRNAs also regulate the silencing of genes by controlling
chromatin-protein interactions as molecular scaffolds. According toncer diagnosis and therapy, Non-coding RNA Research (2016), http://
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plex are bridged together with the help of HOTAIR and the inter-
action of these complexes target the speciﬁc oncogenes and carry
out alterations in histone modiﬁcations, resulting in gene silencing.
Another example of gene silencing by lncRNAs is such that an
ncRNA (CCND1) can allosterically modify the TLS protein through
the transcription of 5'CCDN1 regions when the stimulus of DNA
damage is received [13]. This gene speciﬁc TLS-CBP/p300 interac-
tion induced by conformational alterations of the TLS protein stops
the transcription process of CCDN1. An interesting lncRNA called
MALAT-1, known to be extensively expressed in different types of
predisposed tumours, regulate the functional SR splicing factors,
alternatively splicing to nuclear speckles. An important fact about
lncRNAs is that they can control the genetic changes in response to
intracellular signalling of transcription factors. One foremost
example is the induction of lncRNAs-p21 repressing distinct genes
through the recruitment of hnRNP-K protein. Numerous lncRNAs
are genetically expressed in different types of cancers with
different clinical invasiveness. A two-way ANOVAwith pathological
risk factors and clinical course suggested that HOTAIR oncogene
RNA is a signiﬁcant and eventual biomarker of cancer metastasis
and resulting death. This is because the mRNA proﬁling requires
hundreds of RNA species stratiﬁcation but the use of a single
HOTAIR RNA (lncRNA) provides a novel diagnostic and therapeutic
tool for prior prognosis and management of cancer [14].
3. Proteomic and genetic databases of lncRNAs
The identiﬁcation of a variety of long non coding RNAs requires
the establishment of genetic databases which consists of both
proteomic and genetic information about lncRNAs, including their
molecular functions or functions at the cellular level along with
their associations with other RNAs. Important databases with their
proteomic functions are listed in Table 1.
4. Long non coding RNA (lncRNA) decoy function
The lncRNAs decoy function refers to the pseudo gene class of
lncRNAs functionally plagiaristic to mutations in non coding genes.
A small number of mismatches occur despite originality of se-
quences with the parental gene. This similarity in structure mimics
the structure of mRNA with lncRNAs, inﬂuencing the cellular
function at the genetic level. This lncRNAs decoy function is of
immense importance in cancer metastasis [15]. For instance:
4.1. PTEN
The mutation in PTEN causes the formation of the PTENP1 form
bymismatching the sequence at 18 sites. The untranslated region of
PTENP1 3'-UTR offers a number of regions for the miRNA to bind inTable 1
Databases for long non coding RNA.
Database Functions/Information
LNCipedia Annotated human database lncRNAs transcript sequences and st
DIANA-LncBase Predicted miRNA recognition elements (MREs) on human and m
computationally
CHIPBase An open decoding transcriptional database for regulatory netwo
genes from CHIP-seq data
Noncode v.3.0 Annotation of long non coding RNAs integratively excluding t-R
lncRNAdb The reference database for functional comprehensive annotations
lnRNome Preliminary built compared with human genome program.
The functional
lncRNAs database
A database of mammalian long non protein coding repository tr
Currently, the database contains lncRNAs from Human, Mouse a
Please cite this article in press as: M. Rasool, et al., Non-coding RNAs in ca
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Therefore, a number of miRNAs mimic the structure of PTENP1 to
ﬁght with PTEN [16].
4.2. KRAS
KRAS competes with its pseudo gene KRAS1P to accomplish its
decoy function. In numerous tumours, the expression of KRAS1P is
enhanced with the increased expression of KRAS by binding to 3'-
UTR of KRAS, functioning as a sponge, the miRNA shows positive
correlation [17].
4.3. GAS
The decoy function is also applicable toDNAwhich is depicted by
the Growth Arrest Speciﬁc 5 (GAS 5) function which mimics the
structure of the glucocorticoid response element (GRE) by binding
with the GR transcription factor, interrupting the normal function of
the glucocorticoid receptor (GR). Normally, the GR is activatedwhen
a ligand binds to it and stimulates the GRE to transcribe the genetic
expression of downstream genetic transcripts. The genetic
sequence of Gas 5 forms 6 hairpin conﬁrmations. The structure of
hairpin 5mimics the actual conﬁrmation of the GRE and, as a result,
the GR interactswithGas 5 in spite of theGRE, consequently, halting
the transcription activity of the GR mediated GRE activity [18].
5. Diagnosis and therapeutic considerations using lncRNAs
The association of certain types of cancer with lncRNAs can be
explored by determining the comparison of lncRNAs levels in
cancer cells verses normal cells which must be conﬁrmed through
reverse transcription equantitative polymerase chain reaction (RT-
qPCR). The role of lncRNAs in tumour invasion, metastasis, migra-
tion and progression must also be investigated by in vitro and
in vivo tissue culture techniques. Statistical correlation analysis also
conﬁrms the strong relationship of lncRNAs with progression and
invasion of cancer and also the survival rate of these patients. For
the last few years, the circulating lncRNAs biomarkers have been
given more importance due to cancer diagnosis, prognosis and
designing of fruitful cancer therapeutics [19].
5.1. Prostate cancer (PCa)
The diagnosis of PCa is currently based upon androgen
regulated-serine protease PSA, highly speciﬁc to prostate cancer.
The routine testing of PSA, unfortunately (?), addresses many
problems due to its high speciﬁcation for prostatic hyperplasia and
prostatitis. The diagnosis and therapy of PCa using lncRNAs, such as
DD3, also known as Prostate cancer Antigen 3 (PCA3), is increas-
ingly expressed in such patients, whereas they show no expressionWebsite
ructural patterns www.lncipedia.org
ouse lncRNAs experimentally veriﬁed and http://diana.imis.athena.
innovation.gr/DianaTool
rks of non coding RNAs and protein coding Deepbase.sysu.edu.cn/chipbase
NAs and rRNAs www.ebi.ac.uk/miriam/main/
collections/MIR:00000248
of eukaryotic long non coding RNA (lncRNAs) www.lncrnadb.org
Genome.igib.res.in/lncRNome
anscripts to search a speciﬁc lncRNAs.
nd Rat
www.valadkhanlab.org
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gene speciﬁc to PCa which can be estimated in urine samples [20].
The ﬁrst ever established molecular test for PCa is the PROGENSA
PCA3 test approved by the Food and Drug administration. Multi-
variate analysis conﬁrmed the validity of PCA3 analysis in urine
with a sensitivity of 62% and speciﬁcity of 75%. Another one of the
most investigated lncRNAs in case of PCa is Metastasis Associated
Lung Adenocarcinoma Transcript 1 (MALAT-1) which can be
detected in the plasma of the prostate cancer patient in a highly
expressed form and has been approved as a biomarker of PCa. The
main advantage of using these lncRNAs as diagnostic biomarkers is
that it helps to prevent 30.2e46.5% biopsies in patients having
serum PSA level of 4e10 ng/ml. Researchers are also working on
another lncRNA called PCAT-18 (Prostate Cancer Associated Non-
coding RNA Transcript 18) which is overexpressed in prostate
cancer, progressing from the localized to the metastatic phase and
can be detected highly in the plasma of patients [21].
5.2. Cervical cancer
HOX Transcript Antisense RNA (HOTAIR) is an lncRNA which is
speciﬁc to tumour invasion in cervical cancer. Polycomb Repressive
Complex 2 (PCR2) associates with HOTAIR and undergoes tran-
methylation of H3K27. The HOTAIR expression is increased in the
serum of cervical cancer patients which is also indicative of the
metastatic tumour phase, adenocarcinoma, lymphatic node
metastasis and tumour recurrence [22].
5.3. Colorectal cancer (CRC)
CRC is commonly diagnosed by colonoscopy, stool DNA testing
and faecal occult blood testing which have been used for many
years. The more advanced technique of CLC diagnosis is by using a
microarray of lncRNAs, such as XLOC_006844, LOC152578 and
XLOC_000303, which are upregulated in the plasma of the CRC
patient. These lncRNAs are speciﬁc to CRC which signatures the
strong AUC value of 0.919e0.975 validation level. Furthermore, this
panel of lncRNAs is strongly stable in the plasma of patients and is
considered as a valid CRC biomarker [23].
5.4. Breast cancer
The conventional diagnostic biomarkers used for breast cancer
are the determination of CEA, CA125, CA153 and AFP, but with the
passage of time, more advanced microarray lncRNA analysis has
proven to be more useful with conﬁrmation of RT-qPCR. lncRNAsTable 2
lncRNAs expression in various cancer types and their genomic location.
lncRNAs Cancer type
HOTAIR Liver, colorectal, Breast, Cervical an
MALAT-1 Lung carcinoma
HULC Liver cancer
SPRY4-IT1 Ovarian cancer
PCA3/DD3 Prostate cancer
H19 Gastric cancer
UCA1 Bladder cancer
XLOC_006844 XLOC152578 XLOC_000303 Colorectal cancer
ANRIL SPRY4-IT1 NEAT- 1 Non small cell lung carcinoma
POU3F3 HNF1 A-AS1 SPRY 4-IT 1 Esophageal squamous cell carcinom
RP11-445H22-4 Breast cancer
BANCR Thyroid cancer
BCO40587 Osteosarcoma
CASC2 Endometerial carcinoma
GAS 5 Cervical cancer
NEAT1 Multiple myeloma
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dx.doi.org/10.1016/j.ncrna.2016.11.001RP11-445H22.4 are speciﬁc to breast cancer tissues and can be
detected in the serum of patients with test sensitivity of 92% and
speciﬁcity of 74%, which is signiﬁcantly better than conventional
biomarkers. While it is over expressed in breast cancer tissue
samples, this therapy is still under clinical trial and researchers are
aiming for its application at the commercial level [24] Table 2.
6. Mechanism of action of deregulation of miRNA in cancer
The miRNA processing is a complex process accompanied with
several enzymatic reactions which may at some point link to
tumour initiation and progression due to deﬁciencies in miRNA
components, impairing the production of miRNA. The cancer cell
lines harbouring mutated Exportin 5 gene (XPO5) interferes with
the production and function of miRNA. The role of miRNA dereg-
ulation in Chronic Lymphocytic Leukemia (CLL) was ﬁrst elucidated
in 2002. The miRNA processing is more prone to epigenetic alter-
ations. That is why a number of miRNAs i.e. miR-29, miR-126, miR-
127 and miR-145 are susceptible to methylation [24,25]. Until now
122 epigenetically modiﬁed miRNAs are determined in which 55
miRNAs are speciﬁc to malignancies and 67miRNAs are susceptible
to cancer. These epigenetically modiﬁed miRNAs are located on
chromosome no 1, 7, 11, 14 and 19. Not only are the epigenetic
changes or chromosomal defects responsible for miRNA processing,
several other factors contributing to miRNA deregulation, such as
nucleotide polymorphisms in miRNAs, are also important. As an
example, a pri-miR-196a2 holding single nucleotide poly-
morphisms causes mutation leading to the development of chronic
lymphoid leukemia (CLL), lung, breast and gastric solid tumours
in vivo. The miRNA quantiﬁcation is also controlled by deregulation
of small nucleolar RNAs (snoRNAs) in cancers. In ribosome
biogenesis, snoRNAs (RNU43, RNU44, RNU48) causes 2’-o’- ribose
methylation and interacts with growth arrest speciﬁc 5 gene (GAS
5) in breast cancer. Therefore, it can be inferred that deregulation of
snoRNAs is endogenously controlled to inhibit cancer growth [41].
As described earlier, miRNA functions both as tumour sup-
pressor and oncogene. A multivariate analysis predicted that 50% of
the diseased patients' miRNA lies in the fragile sites of cancer which
clearly demonstrates the crucial role of miRNA in cancer initiation
and progression. Mir-125b-1 (homologue of C.elegans lin-4) is
present on chromosomal locus 11q24 which is absent or show
deleted mutations in patients of chronic breast, lung, liver, cervical
and ovarian cancers [42]. This mir-125b-1gene is also present in B-
cell acute lymphoblastic leukemia patients with an insertion mu-
tation of pr-miRNA in the heavy chain of immunoglobulin. These
studies render this mir-125-b-1 gene as an oncomirs because of itsExpression Gene loci Reference
d Bladder cancer Upregulated 12q13.3 [25]
Upregulated 11 [26]
Downregulated 13q12.2 [27]
Upregulated Multiple loci [28]
Upregulated 13q14 [29]
Upregulated 17q23.2 [30]
Upregulated Multiple loci [31]
Upregulated Multiple loci [32]
Upregulated 5q32-33 [33]
a Upregulated 17q22 [34]
Upregulated 21q21 [35]
Upregulated 19q6 [36]
Downregulated 21q21.2 [37]
Downregulated 22q17.4 [38]
Downregulated 14 [39]
Downregulated 13q31-32 [40]
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vestigations also provide evidence of the miRNA's function as a
tumour suppressor gene. A report was given in which 145 patients
were diagnosed with B cell chronic lymphocytic leukemia (CLL)
when their molecular analysis was carried out, it was observed that
all those patients of CLL were shown to have deletions with
different percentages or suppression of miRNA genes i.e. mir-15-a
or mir-16-1.chromosomal locus 13q14 show 65% deletion in CLL
cases, 16e40% in myeloid leukemia cases, 60% in prostate cancer
cases and 50% in lymphomas. These ﬁndings support the fact that
this miRNA (tumour suppressor gene) is well present in the 30 kb
region. Practitioners have revealed that those CLL cases which have
deletions at chromosomal locus of 13q14 aremore easily prognosed
as compared to the patients with deletions at 11q23 or 17p13
chromosomal locus [43].6.1. miR-15a and miR-16-1 negativley regulate BCL2
BCL2 is an oncogene or antiapoptotic gene that is upregulated in
various cancers such as breast cancer, leukemia, prostate cancer
and lymphomas. The researchers thought that certain mutations
(deletion/down regulation) in mir-16-1 and mir-15a causes the
over expression of BCL2, favouring the development of leukemia
and lymphomas. This fact is further supported by another report
that a germline C to T mutation is present in CLL patients who
showed consequently decreased expression of mir-16-1 gene
leading to lymphogenesis. Thus, this mir-16-1 also has a role in
modulating the immune system and ultimately B-cell differentia-
tion [44].6.2. miRNA proﬁling in cancer diagnosis
The tissue speciﬁc miRNA genes in humans are well determined
throughmiRNAmicroassays and the northern blot techniquewhich
signatures the miRNA expression proﬁles in stem cell studies and
the differentiation destination of undifferentiated cell types during
the development process. Currently, the researchers are conducting
trials to diagnose different classes of cancers by using miRNA
expression proﬁles and designmiRNA biomarkers that aid in cancer
prognosis and diagnosis [45]. Approximately miRNA proﬁles of
about 200 genes are enough to classify different human cancers.
The expression of miRNA in cancerous and normal tissues can be
studied through advanced novel techniques of bead-based ﬂow
cytometry. Through this method, tumours of different tissue origins
are grouped in the same class on the basis of their embryonic
lineage and miRNA expression. This results in the development of
accurate miRNA expression proﬁles of both normal and cancerous
tissues. For instance, the cancers of colon, liver, stomach and
pancreas all possess the same endothelial origin and when they are
clustered together in the same proﬁle, they can show a single
miRNA expression proﬁle [46]. Similarly, tumours ofTable 3
Summary of functions of non coding RNAs [53].
NCRNAs as
Oncogenes or tumour
suppressors
Changes inmiRNA expression such asmiR-155 andmiR-21
hand, miR-15 and miR-16 suppress tumour functionally d
Cancer metastasis miR-10b promote distant metastasis in breast cancer to l
As diagnostic tool miRNA, T-UCRs and lincRNAs proﬁling can be used for di
cancerous tissue types.
Regulatory network Interplay of miRNA, lncRNAs and protein coding genes di
causes cancer
Genetic variations Genetic variations in miRNA genes affect miRNA proﬁling
Epigenetic regulation Epigenetic machinery is controlled by a type of miRNAs c
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This method avoids coherent clustering of the same tumour data-
set. Therefore, the hepatocellular carcinomas are not grouped in the
same class. Hence, miRNA expression proﬁles reﬂect the origin,
developmental history of both normal and cancerous tissues and
metastasis proﬁle of tumours.
The diagnostic path of cancers through miRNA proﬁling is
advanced by comparing the miRNA expression proﬁles of tumours
with those of normal cells. A research reported a miRNA proﬁle of
217 genes was prepared in which 129 miRNAs showed no or low
expression irrespective of their tissue origin. Therefore, globally, it
is taken into consideration that miRNA expression proﬁles of tu-
mours signatures the differentiation stage of the cells when
compared with normal cells regardless of their tissue origin [47].
These conclusions consider miRNAs simply as ‘oncomirs’ which
describe that low or de differentiation in cells causes abnormalities
progressing them towards metastasis. That is why proper miRNA
signatures libraries or miRNA expression proﬁles established which
help in accurate prognosis, diagnosis and treatment of each type of
cancer. The establishment of the miRNA library requires the simple
isolation miRNA from a parafﬁn ﬁxed formalin embedded tissue
which can predict the patient's whole prognosis data. Therapeutics
of cancer based on miRNA proﬁling proves to be a powerful tool for
researchers to deﬁne a proper treatment regimen for every type of
tumour, even ones that are poorly differentiated or histologically
non diagnostic [48].7. Small non coding RNAs in cancer therapeutics
The main concept of cancer therapeutics is based upon the
identiﬁcation of molecular targets that are speciﬁed to cancer. The
speciﬁc biological importance and differential expression of every
type of non coding RNA for speciﬁc cancers may prove to be po-
tential targets. Small non coding RNAs, also known as miRNAs, are
potentially targeted by introducing complementary RNA sequences
exogenously and by blocking miRNA hybridization through its
3'UTR sequences endogenously [49].7.1. Negative regulation of ‘Ras’ by ‘Let-7’ family
The ﬁrst group of oncomirs encoded by let-7 family speciﬁcally
regulate the expression of an oncogene called Ras genes. Ras pro-
teins are the membrane signalling proteins associated with GTPase
speciﬁc for the regulation of cell growth and differentiation. It has
been investigated that about 15e30% of mutations are associated
withmutations in Ras proteins. Therefore, themiRNA that regulates
the expression of this Ras protein controls the cellular proliferation
or tumour growth in check. That is why, it is indicated that let-7
could be used as a good diagnostic marker for non small cell lung
cancer patients because they show poor expression of let-7 and
short operative survival. In vitro studies indicate that tissue cultureforces the cell to become neoplastic, develops high grade lymphoma. On the other
elete lymphocytic leukemia.
ung by downregulation HOX D10 and downregulating RHOC and miR-31.
agnosis and prognosis and allows accurate differentiation between normal and
splay a complex network of interactions in normal cells an d when deregulated
and affect cancer susceptibility
alled epi-miRNAs e.g miR-29 target DNA methyl transferases
ncer diagnosis and therapy, Non-coding RNA Research (2016), http://
M. Rasool et al. / Non-coding RNA Research xxx (2016) 1e86of the human lung adenoma cell line displayed transient cellular
proliferation inhibition in the presence of let-7which suggests that
let-7 is a tumour suppressor gene and that let-7 can be used as a
therapeutic agent in the treatment of lung cancer caused by stim-
ulation of mutation by Ras genes [50].Fig. 1. Therapeutics of cancer through miRNA is based upon either blocking the activity o
suppressor agents. In normal cases, complementary binding of miRNA to the target genes res
the case of miRNA functioning as tumour suppressors, the defects of miRNA biogenesis i
expression proﬁle, ultimately consequences cellular proliferation, angiogenesis, halts apopto
the overexpression of this oncogene due to defects in differentiation tissues at any stage of g
the progression of metastasis and cancer growth.
Please cite this article in press as: M. Rasool, et al., Non-coding RNAs in ca
dx.doi.org/10.1016/j.ncrna.2016.11.0017.2. Association of miRNAs with MYC oncogene
Most human cancers often show an increased expression ofMYC
oncogene which is a potent regulator of growth and is responsible
for both cellular apoptosis and proliferation. miRNA is closely
related to over expression of MYC, resulting in the formation of B-
cell malignancies. Here is an example: when the MYC gene is
translocated [t(8;17)] to the place of mir-142 locus under thef miRNA as oncogenes or by expressing the activity of miRNA functioning as tumour
ults in the induction of apoptosis, cellular growth and ultimately cell death. However, in
s integrated to reduce in mature miRNA and unfortunate miRNA target oncoprotein
sis and tumorigenesis. In the second case, where miRNA is functioning as an oncogene,
rowth suppresses the expression of miRNA target tumour suppressor genes leading to
ncer diagnosis and therapy, Non-coding RNA Research (2016), http://
M. Rasool et al. / Non-coding RNA Research xxx (2016) 1e8 7control of miRNA promoter, it results in the development of B-cell
leukemia. This happens because of the disruption of miRNA pro-
cessing owing to the over expression of MYC and formation of B cell
cancer. The miR-155 is also linked to the transformation of B cells
[51]. Formany years, scientists were trying to explore howRNA that
is non coding for protein and possesses a conserved sequence be-
tween human, mouse and avian genomes could lead to the for-
mation of lymphomas which might become responsible for the
increased expression of MYC. The expression of miR-155 was 100
times increased in Burkitt lymphoma, Hodgkin lymphoma and B
cell lymphomas. This means that miR-155 functions as an oncogene
by interaction with MYC, however, in normal circumstances it tar-
gets those genes that works antagonistically with the MYC
pathway. mir-155 expression is also seen to work in other carci-
nomas, such as breast carcinoma, where its expression is up
regulated which is meant for its distinct functions other than
haematopoietic cells [52].
7.3. Therapeutic restoration of miRNA with micromolecules
The reason of downregulated expression of miRNA functioning
as tumour suppressors is miRNA loci deletion or epigenetic
silencing through CpG island hypermethylation through the pro-
moter of miRNA genes. Improving the biogenesis of miRNA and
restoring the miRNA through the direct intake of miRNA formu-
lations can solve the problem. In this regard, hypomethylation
agents such as decitabine or 5-azacitydine are useful to reserve
the miRNA epigenetic silencing [50]. These are the approved
treatments for myelodysplastic syndromes by downregulating the
expression of several non coding RNAs and mRNAs. Another
therapeutic approach is the utilization of a small biomolecule
called enoxacin which is a derived ﬂuoroquinolone compound
applied usually as an antibacterial agent is a powerful up regu-
lator of miRNA production by interacting with TAR RNA-binding
protein 2 (TARBP2). Colon cancer cells have been successfully
treated with enoxacin in vitro. Another study also predicted that
enoxacin enhanced the expression of about 24 miRNAs in mice
models, retarding the tumor growth in xenografts in cancer albino
mice models. These studies clearly demonstrate that the anti-
cancer activity is through the regulation of the miRNA mechanism
by enoxacin. This illustration highlights the restoration of dis-
rupted miRNA spectrum downregulated in cancer cells [37]
Table 3.
8. Conclusion
Non coding RNAs involving lncRNAs and miRNAs are potential
therapeutic targets as they possess biological signiﬁcance to be
used as strong biomarkers for the diagnosis and prognosis of a
number of cancers. The elucidation of the mechanism of non
coding RNAs requires systemic study. However, the establishment
of RNA proﬁling using bioinformatics tools and development of
NCRNA databases is also very important. Future perspectives
which are based upon non coding RNA localization, their genetic
proﬁles and their mechanism elucidate their key roles in gene
expression regulation. The utilization of antagomiRs, combined
with cholesterol, could play a fundamental role to inhibit onco-
mirs activity in human cancers. On the other hand, miRNAs used
as tumour suppressors, such as those of the let-7 family, could be
over expressed for the treatment of speciﬁc types of cancers. In
the future, the use of synthetic antisense oligonucleotides
encoding complementary sequences of mature oncomirs, also
known as anti-miRNA oligonucleotides (AMO), might be useful to
inhibit the function of oncomirs and halt tumour growth. There-
fore, the non coding protein RNA (NCRNAs) might become thePlease cite this article in press as: M. Rasool, et al., Non-coding RNAs in ca
dx.doi.org/10.1016/j.ncrna.2016.11.001magic bullet that provides insight into the treatment of all types of
cancers Fig. 1.
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